Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment

Basit Öğe Kaydı
dc.authoridAltindis, Mustafa/0000-0003-0411-9669
dc.authoridçakır, emre/0000-0003-0411-8818
dc.authoridVARIM, Ceyhun/0000-0002-8369-0857
dc.authorwosidAltindis, Mustafa/L-9899-2014
dc.authorwosidBilir, Filiz/JYO-4231-2024
dc.authorwosidçakır, emre/JVZ-2045-2024
dc.authorwosidVARIM, Ceyhun/HTM-7510-2023
dc.contributor.authorCakir, E.
dc.contributor.authorSaydan, D.
dc.contributor.authorGulbagci, B.
dc.contributor.authorOzen, M.
dc.contributor.authorUgurlu, I
dc.contributor.authorDemirci, A.
dc.contributor.authorBilir, F.
dc.date.accessioned2024-05-19T14:40:30Z
dc.date.available2024-05-19T14:40:30Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstract- OBJECTIVE: Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. Most of the studies in the literature compared the immuni-ty in cancer patients with a cross-sectional cohort or retrospectively. Our study investigated Sino-vac-CoronaVac COVID-19 vaccine immunogenici-ty and compared it with natural COVID-19 disease in cancer patients during their cancer therapy.PATIENTS AND METHODS: A total of 111 pa-tients with cancer and who are on active treat-ment were included in the study. This is a sin-gle-center study and was designed prospec-tively. Two group of patients were included in the study, natural disease and vaccinated group.RESULTS: A total of 111 patients were in-cluded in the study, 34 of whom had natural COVID-19 disease. Antibody levels following the first dose vaccine were 0.4 (0-1.9) U/ml while af-ter the second dose of vaccine were 2.6 (1.0-7.25) U/ml. Immunogenicity levels were 82.4% in the natural disease group and 75.8% in the vaccinated group after the second shot of the vaccine. Immunogenicity rate was significantly higher in non-chemotherapy (receiving immu-notehrapy/targeted therapy or biologic agent) group compared to chemotherapy drug (92.9% vs. 63.3%, p=0.004). There was a difference be-tween the antibody levels following the first and second vaccination [median (IQR): 0.3 (0-1.0) and 3.3 (2.0-6.7), p=0.001, respectively].CONCLUSIONS: The present study revealed that the Sinovac-CoronaVac vaccine showed an acceptable immunogenicity following two shots in cancer patients who were receiving ac-tive systemic therapy. On the other hand, nat-ural disease immunogenicity was higher than vaccinated group.en_US
dc.identifier.endpage4315en_US
dc.identifier.issn1128-3602
dc.identifier.issue9en_US
dc.identifier.pmid37203857en_US
dc.identifier.scopus2-s2.0-85159769767en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage4309en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4972
dc.identifier.volume27en_US
dc.identifier.wosWOS:000999896900029en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCovid-19en_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectImmunogenecityen_US
dc.titleComparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu